Transcutaneous Electric Muscle Stimulation (TEMS) in Septic Patients
Effect of Transcutaneous Electric Muscle Stimulation on Muscle Volume in Patients With Septic Shock
1 other identifier
interventional
8
1 country
1
Brief Summary
A growing number of critically ill patients survive intensive care to be discharged from hospital. However, critical illness and prolonged bedrest are associated with muscle wasting with subsequent implications for recovery of normal physical function. Thus, one year after discharge, survivors of septic shock have reported prolonged and severe impairment of physical function. Early interventions employed in the ICU to counteract loss of muscle mass may potentially improve physical outcome and reduce the overall burden of critical illness. As a potential supplement to physical therapy, transcutaneous electric muscle stimulation (TEMS) is a non-invasive method directed at maintaining skeletal muscle function through artificially induced contractions that are independent of patient efforts. TEMS has previously proven effective at preventing loss of muscle mass and force in a number of non-ICU patient groups, but has only been assessed sparsely in an ICU population where both immobilisation and systemic inflammation are present. Therefore, the aim of the present study was to assess the effect of early TEMS on muscle volume in patients admitted to the intensive care unit with septic shock. The investigators hypothesized that this intervention would preserve muscle volume during septic shock.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jan 2008
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2009
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2009
CompletedFirst Submitted
Initial submission to the registry
February 18, 2010
CompletedFirst Posted
Study publicly available on registry
February 19, 2010
CompletedFebruary 19, 2010
January 1, 2010
1.2 years
February 18, 2010
February 18, 2010
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Volume of quadriceps muscles were calculated after 3-D reconstruction based on CT scans
Interventions
After randomization of the quadriceps muscles TEMS is applied on the intervention side for 7 consecutive days, 60 minutes per day.
Eligibility Criteria
You may qualify if:
- patients with septic shock admitted to the ICU of Rigshospitalet
- written informed consent from patient or proxy
You may not qualify if:
- diabetes
- a focus of infection in or trauma to the lower extremities
- a predicted ICU stay of less than seven days
- severe respiratory or circulatory instability that precluded transportation of the patient to the CT scanner
- patients receiving hihg dose corticosteroids (equivalent to methylprednisolone 1mg/kg/day or more)
- pregnancy
- severe psychiatric disorder
- \> 72 hours since the diagnosis of septic shock was established
- patient receiving neuromuscular blocking agents
- pre-existing neuromuscular disease
- acute compression/affection of central or peripheral nerves relevant to the lower extremities
- BMI \> 30
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Rigshospitalet, Denmarklead
- University of Copenhagencollaborator
Study Sites (1)
Dept. of Intensive Care, Rigshospitalet, University of Copenhagen
Copenhagen, 2100, Denmark
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jesper B Poulsen, MD
Rigshospitalet, University of Copenhagen
- STUDY CHAIR
Kirsten Møller, MD, PhD, DMSci
Rigshospitalet, University of Copenhagen
- STUDY CHAIR
Anders Perner, MD, PhD
Rigshospitalet, University of Copenhagen
- STUDY CHAIR
Henrik Kehlet, MD, DMSci
Rigshospitalet, University of Copenhagen
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- PREVENTION
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
February 18, 2010
First Posted
February 19, 2010
Study Start
January 1, 2008
Primary Completion
April 1, 2009
Study Completion
April 1, 2009
Last Updated
February 19, 2010
Record last verified: 2010-01